Cartesian SEC Filings

Cartesian Therapeutics, Inc. reported that a director received new equity awards in the form of common stock and stock options. On 12/16/2025, the director was granted 5,800 shares of common stock at a price of $0, recorded as an acquisition of non-derivative securities. Following this grant, the director beneficially owned 5,800 common shares directly.

The filing also discloses a derivative award of a stock option for 17,200 shares of common stock with an exercise price of $8.29, granted on 12/16/2025 and expiring on 12/15/2035. The 5,800-share restricted stock unit grant will vest in three equal annual installments so that all underlying shares are fully vested on December 16, 2028. The 17,200-share stock option will vest in 36 equal monthly installments and is also scheduled to be fully vested on December 16, 2028.

Cartesian Therapeutics, Inc. filed an initial ownership report for a board member of the company. The filing identifies the reporting person as a director of Cartesian Therapeutics, Inc. (ticker RNAC) and confirms that the form is filed for one reporting person only.

According to the explanation of responses, the director currently has no securities beneficially owned in Cartesian Therapeutics, either directly or indirectly. A power of attorney (Exhibit 24) authorizes an attorney-in-fact, Matthew Bartholomae, to sign the form on behalf of the reporting person.

Cartesian Therapeutics, Inc. reported that its Board appointed Adrian Bot, M.D., Ph.D. as a Class II director, serving until the 2027 annual meeting, and initially joining the Science and Technology Committee. Dr. Bot is a veteran biopharma R&D executive with extensive experience in immune, cell and gene therapies, including prior senior roles at Kite Pharma and Capstan Therapeutics.

As compensation, he will receive annual cash retainers of $40,000 for Board service and $7,500 for committee service, an option to purchase 17,200 shares at an exercise price of $8.29 per share, and 5,800 restricted stock units, all vesting over three years subject to continued service. The Board also adopted an updated Code of Business Conduct and Ethics applying to all directors, officers and employees, which enhances guidance on protection and use of company assets and information, including bring-your-own-device practices, and replaces the prior code without any waivers.

Cartesian Therapeutics, Inc. (RNAC)11/18/2025. The director gifted 20,000 shares of common stock, reported with transaction code G at a stated price of $0 per share, which is typical for a charitable or family transfer. After this transaction, the director held 53,533 shares directly. Additional shares are reported as indirectly held, including 383,796 shares in a trust for the benefit of the director’s spouse and children, as well as other trusts and custodial accounts for family members.

Cartesian Therapeutics (RNAC) reported initial Phase 2 data for Descartes-08 in systemic lupus erythematosus and outlined plans to expand the program into myositis. In the open-label SLE study, 100% of participants who reached Month 3 follow-up (n=3) achieved LLDAS, with disease remission (DORIS) in two of three. Safety observations noted outpatient administration without preconditioning, mostly mild adverse events, and no CRS or ICANS.

Correlative biomarkers showed a statistically significant (p<0.01) decline in proinflammatory cytokines (IL7, IL10, CCL20, ST1A1) and decreased plasmacytoid dendritic cells, supporting expansion into myositis. The planned randomized, double-blind, placebo-controlled myositis Phase 2 will enroll up to 50 patients, use six weekly outpatient infusions, assess a Week 24 primary endpoint, and include an interim analysis after ten patients reach the endpoint. An IND is planned by the end of 2025, with trial start targeted for the first half of 2026. The company will pause further SLE work on Descartes-08 and development of Descartes-15 to prioritize Descartes-08 in myasthenia gravis (Phase 3) and myositis.

Cartesian Therapeutics (RNAC) filed its Q3 2025 10‑Q, reporting operating progress and updated financials. Cash and cash equivalents were $143.4 million ($145.1 million including restricted) and management states this will fund current planned operations for at least the next 12 months.

Total revenue was $0.5 million in the quarter and $1.9 million year‑to‑date, primarily from grants. Research and development expense was $13.8 million in Q3 ($43.3 million YTD), and general and administrative was $7.7 million in Q3 ($23.3 million YTD). The company recorded a Q3 net loss of $35.9 million and a year‑to‑date net loss of $37.7 million, reflecting operating spend and non‑cash fair‑value changes.

The contingent value right liability decreased to $369.0 million from $395.5 million, with $7.8 million distributed in March 2025 per the CVR terms. Shares outstanding were 26,003,606 as of October 31, 2025. The company remains focused on clinical‑stage cell therapies for autoimmune diseases.

Cartesian Therapeutics, Inc. announced its financial results for the quarter ended September 30, 2025. The company furnished a press release with details as Exhibit 99.1 to a Form 8-K.

The Item 2.02 information, including Exhibit 99.1, is furnished and not deemed “filed” under Section 18 of the Exchange Act, nor incorporated by reference except as expressly stated. The filing lists the company’s common stock trading on The Nasdaq Stock Market LLC under the symbol RNAC.

Cartesian Therapeutics (RNAC) announced board leadership changes and a bylaws update. On October 29, 2025, Carrie S. Cox resigned from the Board, effective immediately, following her appointment as Executive Chair of another public company. The company stated her resignation was not the result of a disagreement regarding operations, policies, or practices.

The Board appointed Carsten Brunn, Ph.D., as Chairman; named Patrick Zenner, M.B.A., as Lead Independent Director; and appointed Kemal Malik, M.B.B.S., as Chair of the Compensation Committee. Dr. Brunn will not receive additional pay for serving as Chairman, while Mr. Zenner and Dr. Malik will be compensated per the Non-Employee Director Compensation Program.

Also on October 29, 2025, the Board approved amended and restated bylaws to include references to the Lead Independent Director role. On October 30, 2025, the company furnished a press release announcing Dr. Brunn’s appointment.

Cartesian Therapeutics (RNAC) reported a Form 4 for its Chief Accounting Officer, June Ann Seymour, documenting an equity award. On 10/27/2025, Seymour received an employee stock option50,000 shares at an exercise price of $8.85 per share, expiring on 10/27/2035.

The option vests as to 25% on 10/27/2026, with the remaining underlying shares vesting in three equal annual installments so that all shares are fully vested on 10/27/2029. The filing lists ownership of the derivative security as Direct (D) with 50,000 derivative securities beneficially owned following the reported transaction.